Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon

J Clin Oncol. 2020 Feb 20;38(6):529-531. doi: 10.1200/JCO.19.02988. Epub 2019 Dec 27.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Humans
  • Interferon alpha-2*
  • Ipilimumab
  • Melanoma*
  • Nivolumab
  • United States

Substances

  • Interferon alpha-2
  • Ipilimumab
  • Nivolumab